GH Research is a clinical-stage pharmaceutical company developing therapies for psychiatric and neurological disorders. The company focuses on mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates, with its lead program, GH001, being a pulmonary inhalation formulation currently in Phase 2b trials for treatment-resistant depression (TRD). The portfolio also includes GH002, an intravenous formulation, and GH003, an intranasal formulation. Clinical development programs are ongoing for TRD, bipolar II disorder with a depressive episode, and postpartum depression. Founded in 2018, the company develops treatments with rapid onset of action and durable effects for difficult-to-treat depression.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage ghres.com
Sector Healthcare IR page investor.ghres.com
Tags
psychiatric disorders, treatment-resistant depression, bipolar disorder, postpartum depression, psychedelic therapy, clinical-stage, pulmonary inhalation, intravenous formulation, intranasal formulation, GH001, GH002, GH003, mebufotenin, 5-MeO-DMT
Press page —

Metrics

Valuation  
Market cap $ 1.612B
Market cap (USD) $ 1.612B
P/E -23.72
PEG —
P/BV 4.48
P/S —
P/OCF -31.17
P/FCF -31.09
Dividend yield —
Turnover / mcap —
Returns  
ROE -21.0%
ROI -143.6%
ROIC -135.5%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 288.23M 188.273M 226.3M 254.362M 279.924M 5.912M
Net profit -48.258M -38.961M -35.587M -22.456M -9.202M -446K
Free cash flow -43.673M -42.334M -33.436M -26.266M -15.387M -330K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 12.7 7 5.8 9.71 23.33 —
Price performance 12m 0.81 0.21 -0.4 -0.58 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (USD) 296,000 338,000 8.55M 20.5M 29.8M 35M 38.8M
↳ 5y CAGR +159.8% +158.2%
Reported Mar 28, 2022 Mar 28, 2022 Mar 28, 2022 Mar 9, 2023 Mar 7, 2024 Feb 27, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

• Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visit

• TRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly after

• PPD pivotal program — initiation targeted for H2 2027

• Vanina Popova, MD, appointed Chief Development Officer — Formerly Clinical Development at J&J, lead author of pivotal Spravato® trial publication

• Cash, cash equivalents and marketable securities of $350.6 million as of September 30, 2026

DUBLIN, November 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended September 30, 2026, and provided a business update.

Business Updates

Global Pivotal Program of GH001 in TRD

The final results of our Phase 1 trial GH001-HV-106 in healthy volunteers support one fixed dose of GH001 per treatment visit with our novel GH001 Aerosol Delivery System (ADS).

☐

GH Research PLC (the “Company”) announces the presentation of data from its GH001-TRD-201 and GH001-BD-202 clinical trials at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 10-13, 2026, in Munich, Germany. The data will be presented in three posters during Poster Session 2 on October 11, 2026, by Prof. Wiesław J. Cubała, Prof. Bernhard T. Baune, and Dr. Max de Leeuw.

The Company will also sponsor an industry satellite symposium titled “Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants” at ECNP on October 10, 2026.

1

1

GH Research PLC will hold one-on-one investor meetings during the Morgan Stanley 24th Annual Global Healthcare Conference, which is scheduled to take place from September 14 – 16, 2026, in New York.

1

Prompts

GH Research PLC (ticker GHRS), listed in United States.

ETFs Holding GH Research PLC

ETF Weight in ETF Shares Market value As of
PSIL 4.89% 102,038 $ 1.864M Nov 17, 2026